<recall-number id="D-324-2013">
                                <product-type>Drugs</product-type>
                                <event-id>64267</event-id>
                                <status>Ongoing</status>
                                <recalling-firm>Gilead Sciences, Inc.</recalling-firm>
                                <city>Foster City</city>
                                <state>CA</state>
                                <country>US</country>
                                <voluntary-mandated>Voluntary: Firm Initiated</voluntary-mandated>
                                <initial-firm-notification>E-Mail</initial-firm-notification>
                                <distribution-pattern>Nationwide in USA, Canada, and UK (Gilead facility in Cork Ireland). Cork fa
cility distributed to Germany/Austria, Italy and Spain.</distribution-pattern>
                                <classification>Class I</classification>
                                <product-description>Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA  94404, UPC 3 61958 01011 5; NDC 61958-0101-1.</product-description>
                                <code-info>Lot #: B120217A, Exp 05/15 - US Distribution
</code-info>
                                        <product-quantity>3,181 vials </product-quantity>
                                        <reason-for-recall>Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).</reason-for-recall>
                                        <recall-initiation-date>01/31/2013</recall-initiation-date>
                                        <report-date>05/22/2013</report-date>
                        </recall-number>